Schering-Plough expands Latin American presence, restructures operations in Brazil

By Elaine Rigoli

Tampa, Fla., June 21 - Schering-Plough Corp. said Wednesday that it will establish Schering-Plough Produtos Farmaceuticos Ltda. as a wholly owned country operation based in Sao Paulo, Brazil, to market its core products, and will restructure its agreement with Mantefarma, a privately held company in Brazil.

"Investing in the Latin America region and other emerging markets represents another step in our journey to transform Schering-Plough into a global, high-performance health care company," chairman and chief executive officer Fred Hassan said in a news release.

Schering-Plough entered into an agreement in 1991 with Mantefarma to market and distribute several products through Industria Quimica e Farmaceutica Schering-Plough, SA.

Under a new agreement, Mantefarma, which will now be known as Mantecorp, will continue to manufacture a number of Schering-Plough primary-care products.

Schering-Plough Produtos Farmaceuticos will assume commercial responsibility for Schering-Plough specialty care products, including Peg-Intron (peginterferon alfa-2b), Temodal (temozolomide) and Caelyx (pegylated liposomal doxorubicin HCl).

The company also will market the primary-care products Zetia (ezetimibe), Zetsim (ezetimibe/simvastatin), Claritin (loratadine), Clarinex (desloratadine) and Nasonex (mometasone furoate monohydrate).

Schering-Plough is a global health care company based in Kenilworth, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.